BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare Infectious Diseases Disease Analysis: Pneumococcal Vaccines

September 02, 2022

Prevnar 20, the successor to Pfizer's blockbuster Prevnar 13, and Vaxneuvance were approved back-to-back by the FDA in June 2021 and July 2021, respectively. Since then, Prevnar 13’s market share has been cannibalized to an extent as both vaccines are now recommended by the Advisory Committee on Immunization Practices (ACIP) at parity – superseding prior recommendations for Prevnar 13 in elderly populations in the US – with a sequential dose of Merck’s Pneumovax 23 being required when Vaxneuvance is used. European approval has also been granted to both Vaxneuvance and Prevnar 20 (as Apexxnar) for use in adults, but guidelines in the five major European markets (France, Germany, Italy, Spain, and the UK) are yet to be updated to include recommendations for either. 

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Pneumococcal (Streptococcus pneumoniae) Vaccines (Antibacterial)
Back to the top Back to the top